Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study

OBJECTIVES: Erenumab is a human anti‐calcitonin gene‐related peptide receptor monoclonal antibody approved for migraine prevention. Global studies have demonstrated its efficacy in chronic and episodic migraine (EM). Here we report the outcomes from a Phase 3 study of erenumab in Japanese patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeshima, Takao, Sakai, Fumihiko, Hirata, Koichi, Imai, Noboru, Matsumori, Yasuhiko, Yoshida, Ryuji, Peng, Cheng, Cheng, Sunfa, Mikol, Daniel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361926/
https://www.ncbi.nlm.nih.gov/pubmed/34153117
http://dx.doi.org/10.1111/head.14138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361926/
https://www.ncbi.nlm.nih.gov/pubmed/34153117
http://dx.doi.org/10.1111/head.14138

Ejemplares similares